The FDA has recently approved a new drug from Eli Lilly for people with atopic dermatitis, a condition characterized by itchy skin that can lead to social stigmatization and discomfort. The drug, EBGLYSS, targets the action of a cytokine believed to be the primary driver behind atopic dermatitis. It is approved for adults and children 12 years or older with moderate-to-severe atopic dermatitis, and aims to transform the lives of those affected by the condition. Atopic dermatitis typically causes red, cracked, and swollen skin that may weep clear fluid or blood and then crust over.
Atopic dermatitis is more common among girls and women, as well as in individuals from families with a history of the condition or allergies such as hay fever and asthma. It often appears during infancy or childhood, though it can develop at any age. While there are existing topical and other drug treatments available for atopic dermatitis, finding an effective controlling treatment can be challenging. EBGLYSS inhibits the production of IL-13, a cytokine associated with atopic dermatitis, and provides a new option for dermatologists treating the condition.
Dr. Tien Nguyen, a dermatologist involved in the clinical trials leading to EBGLYSS’ approval, explained that atopic dermatitis results from pro-inflammatory cytokine activity. Cytokines such as IL-4, IL-13, and IL-31 play a role in causing inflammation and itching associated with the condition. EBGLYSS specifically targets IL-13, making it a valuable addition to the treatments available for atopic dermatitis. It is recommended to use one cytokine-targeting drug at a time for safety reasons rather than targeting multiple cytokines simultaneously.
EBGLYSS was approved by the FDA based on the results of clinical trials, including the ADvocate trials and the ADhere study. The drug is administered through injections and has shown promising results in improving skin clarity, with 38% of participants achieving clear or nearly clear skin after 16 weeks. Common side effects of EBGLYSS include eye and eyelid inflammation, injection site reactions, and shingles. Despite these side effects, the drug has been shown to significantly improve quality of life for patients with atopic dermatitis.
Atopic dermatitis can have a significant impact on an individual’s physical comfort, emotional well-being, and overall quality of life. Dr. Hannah Kopleman shared a patient’s experience with atopic dermatitis, highlighting how the condition affected their sleep, work, social interactions, and self-esteem. After successful treatment with biologics like EBGLYSS, the patient reported fewer flare-ups, improved symptoms, and a dramatic increase in quality of life. Effective treatments like EBGLYSS provide patients with confidence and can help manage the condition.
Drugs like EBGLYSS offer dermatologists a new and effective tool to tailor treatments for patients with atopic dermatitis, ultimately giving them their confidence and life back. By targeting specific cytokines associated with the condition, biologic drugs like EBGLYSS can significantly improve symptoms and quality of life for those affected by atopic dermatitis. The FDA’s approval of these innovative treatments represents a significant step forward in managing and treating atopic dermatitis effectively.
